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INTRODUCTION 
Today in the United States there is a high demand and 
correspondingly a huge market for dietary supplements.1  
Accordingly, any regulatory policy in the area of dietary supplements 
has the potential to affect a large portion of the population.2  About 
sixty percent of Americans take dietary supplements in one form or 
another.3  The results of a recent American Dietetic Association 
survey indicate that approximately forty percent of adults take herbal 
remedies and over eighty percent use vitamin and mineral 
supplements.4  Yet, herbal supplements are potentially dangerous 
when taken alone, or in combination with prescription drugs.5  For 
example, ginkgo biloba has been linked to excessive bleeding and 
stroke.6  A recent survey found that twelve percent of herbal 
 
 ∗ J.D. Candidate 2003, Seton Hall University School of Law; B.S. Dietetics 1996, 
University of Rhode Island. 
 1 See Arthur A Levin, RX News: Dietary Supplement Safety Concerns, HEALTHFACTS, 
June 2001, available at http://www.findarticles.com/cf_0/m0815/2001_June/75286 
633/print.jhtml (on file with author). 
 2 Department of Health and Human Services, Office of the Inspector General, 
Adverse Event Reporting for Dietary Supplements: An Inadequate Safety Valve (Apr. 2001), 
available at http://oig.hhs.gov/oei/reports/oei-01-00-00180.pdf (on file with author) 
[hereinafter HHS Report]. 
 3 Id. 
 4 Jacqueline Stenson, The Herbal Frontier: The Promise and Peril of Supplements, at 
http://www.msnbc.com/news/522365.asp (last visited Apr. 7, 2002) (on file with 
author). 
 5 See infra note 46. 
 6 See HHS Report, supra note 2.  The HHS Report noted that the FDA 
commissioner stated, “[a] small but disturbing number of these products have a 
potential for harm or bear unsupported claims.  In this context, a rapidly expanding 
industry and a changing demographic of consumers eager to manage their own 
health care needs provide a significant regulatory challenge.”  Id. at 7. 
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supplement consumers experience side effects from these products.7 
Prior to the passage of the Dietary Supplement Health and 
Education Act (“DSHEA”),8 the Food and Drug Administration 
(“FDA”) had significantly more control over dietary supplements.9  At 
that time, the FDA categorized dietary supplements as either drugs or 
food additives, both of which require approval before marketing.10  
The DSHEA altered this scheme by taking dietary supplements out of 
the food additive category.11  The DSHEA categorized dietary 
supplements as foods, a category over which the FDA has no power to 
require clearance prior to marketing.12 
 
 7 Id. 
 8 Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 
108 Stat. 4325 (codified as amended in scattered sections of 21 U.S.C.). 
 9 Lauren J. Sloane, Herbal Garden of Good and Evil: The Ongoing Struggles of Dietary 
Supplement Regulation, 51 ADMIN. L. REV. 323, 324 (1999). 
 10 Robert G. Pinco & Todd H. Halpern, Guidelines for the Promotion of Dietary 
Supplements: Examining Government Regulation Five Years After Enactment of the Dietary 
Health and Education Act of 1994, 54 FOOD & DRUG L.J. 567, 568-69 (1999). 
 11 Id. 
 12 Pinco & Halpern, supra note 10, at 569.  The FDA requires premarket approval 
of food additives and for new drug application. HHS Report, supra note 2, at 6.  The 
FDA “is a scientific regulatory agency responsible for the safety of the nation’s 
domestically produced and imported foods, cosmetics, drugs, biologics, medical 
devices, and radiological products.”  U.S. Food and Drug Administration, Center for 
Food Safety and Applied Nutrition, Center for Food Safety and Applied Nutrition Overview, 
at http://www.cfsan.fda.gov/~lrd/cfsan4.html (last updated Aug. 15, 2001) (on file 
with author).  The FDA’s principal function is consumer protection.  Id.  The FDA is 
the “leading food and drug regulatory agency in the world,” and “is part of the 
Executive Branch of the United States Government within the Department of Health 
and Human Services (DHHS) and the Public Health Service (PHS).”  Id.  The 
following table illustrates the differences between regulatory mechanisms for 
different product classes as contained in the HHS Report: 
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The DSHEA was passed in 1994, “largely in response to industry 
pressure.”13  The act amended the Food Drug & Cosmetic Act 
(“FDCA”).14  Following the enactment of the DSHEA in 1994, which 
decreased the FDA’s control over dietary supplement manufacturers, 
the dietary supplement market increased tremendously.15  Since 1994, 
dietary supplement sales have nearly doubled—from $8.6 billion to 
$16 billion.16  This boom is due “in no small part” to the DSHEA.17 
The FDA Commissioner, Jane E. Henney, M.D., stated that the 
purpose of the DSHEA was to grant the FDA power over dangerous 
supplements without interfering with consumers’ ability to access 
dietary supplements in general.18  The congressional findings relating 
to the DSHEA are illustrative of the reasoning behind the enactment 
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∗FDA does not collect or evaluate all adverse events on all conventional food.  Excluded in this system 
are the investigations FDA conducts following food-borne illness outbreaks. 
∗∗Monograph drugs are typically over-the-counter drugs that must adhere to specific safety standards set 
out for each ingredient and do not undergo clinical testing. 
∗∗∗NDA is a new drug application that all prescription drugs and some over-the-counter drugs must 
submit to FDA prior to market.  This application must include data that demonstrates the safety and 
efficacy of the product. 
HHS Report, supra note 2, at 6. 
 13 Roseann B. Termini, Pharmanex, Inc. v. Shalala: A Wake Up Call For 
Congress and a Not So Bitter Pill For the FDA, 26 OHIO N.U. L. REV. 269, 277 
(2000). 
 14 Bruce H. Schindler, Where There’s Smoke There’s Fire: The Dangers of the 
Unregulated Dietary Supplement Industry, 42 N.Y.L. SCH. L. REV. 261, 270 (1998).  “The 
Federal Food, Drug, and Cosmetic Act (FFDCA) authorizes the Food and Drug 
Administration (FDA) to regulate foods, cosmetics, drugs and medical devices.”  
Michigan State University, Institute for Environmental Toxicology, The Federal Food, 
Drug, and Cosmetic Act, at http://www.iet.msu.edu/Regs/fedfoodact.htm (last 
modified July 24, 1999) (on file with author).  The purpose of the  FDCA is to ensure 
“that foods are pure and wholesome, safe to eat, and produced under sanitary 
conditions; that cosmetics are safe and made from appropriate ingredients; that 
drugs and devices are safe and effective for their intended uses; and, that all labeling 
and packaging is truthful, informative, and not deceptive.”  Id. 
 15 Iona N. Kaiser, Dietary Supplements: Can the Law Control the Hype?, 37 HOUS. L. 
REV. 1249, 1250 (2000). 
 16 Stenson, supra note 4. 
 17 Pinco & Halpern, supra note 10, at 567. 
 18 Termini, supra note 13, at 281. 
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of the DSHEA in its present form.19  Among other things, the 
congressional findings emphasized the enormity of the dietary 
supplement industry.20  The findings further noted that although the 
government should act against unsafe or adulterated products, the 
government should not impose “unreasonable regulatory barriers” 
for dietary supplements that are “safe within a broad range of 
intake.”21  By removing some regulatory barriers, the DSHEA has 
made dietary supplements of all qualities widely available to 
consumers.22  Thus, consumers face a larger risk of harm, perhaps 
serious harm, from the effects of these dietary supplements.23  In 
allowing dietary supplements to enter the market without first 
requiring some regulatory review, such as testing for the safety and 
efficacy of the product, the consumer is, in all probability, subjected 
to unknown health risks and effects. 
This Comment will address the DSHEA, the risks its laxity 
imposes on consumers, proposals to improve the current system and 
reduce these risks, and will ultimately recommend a change in the 
current scheme to protect consumers from these potentially 
 
 19 Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-417, 
sec. 2, 108 Stat. 4325, 4326 (Congressional Findings). 
 20 Id.  Regarding the enormity of the dietary supplement industry, the 
congressional findings noted, in pertinent part: 
 . . . (9) national surveys have revealed that almost 50 percent of the 
260,000,000 Americans regularly consume dietary supplements of 
vitamins, minerals, or herbs as a means of improving their nutrition; 
(10) studies indicate that consumers are placing increased reliance on 
the use of nontraditional health care providers to avoid the excessive 
costs of traditional medical services and to obtain more holistic 
consideration of their needs; . . . ; (12)(A) the nutritional supplement 
industry is an integral part of the economy of the United States; 
(12)(B) the industry consistently projects a positive trade balance; and 
(12)(C) the estimated 600 dietary supplement manufacturers in the 
United States produce approximately 4,000 products, with total annual 
sales of such products alone reaching at least $4,000,000,000 . . . . 
Id. 
 21 Id.  The Congressional Findings provided, in pertinent part, that: 
. . . (13) although the Federal Government should take swift action 
against products that are unsafe or adulterated, the Federal 
Government should not take any actions to impose unreasonable 
regulatory barriers limiting or slowing the flow of safe products and 
accurate information to consumers; (14) dietary supplements are safe 
within a broad range of intake, and safety problems with the 
supplements are relatively rare; and (15)(A) legislative action that 
protects the right of access of consumers to safe dietary supplements is 
necessary in order to promote wellness . . . . 
Id. 
 22 Pinco & Halpern, supra note 10, at 568. 
 23 See id. 
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dangerous and highly available dietary supplements.  In Part I, this 
Comment discusses the DSHEA as it operates today and the FDA’s 
power under the present regulatory scheme.  Part II addresses special 
cases in which the courts have accepted FDA’s efforts to exclude 
street drugs, certain ingredients and other products from being 
considered dietary supplements.  Part III describes some of the 
legislative actions taken by the states in reaction to the lax federal 
scheme.  The Comment concludes in Part IV, analyzing a range of 
possible alternatives and changes to the DSHEA, and proposing a 
solution to help remedy the dangers created by the current DSHEA 
scheme without requiring pre-market clearance.  This solution 
involves the utilization and expansion of present efforts, in addition 
to three changes which would require legislative action: shifting the 
burden of proving a product’s safety onto the manufacturer, granting 
the FDA power to act against dietary supplements as a class rather 
than individually, and granting prescription status to supplements 
that are dangerous when taken in excess of the amount suggested on 
the label, when likely to be used in this manner. 
I.  THE DSHEA 
A.  General Provisions 
The DSHEA created a new definition for “dietary supplement.”24  
This broad definition includes a wide range of products.25  A “dietary 
supplement,” as explained by the FDA’s official website, 
• is a product (other than tobacco) that is intended to 
supplement the diet that bears or contains one or more of 
the following dietary ingredients: a vitamin, a mineral, an 
herb or other botanical, an amino acid, a dietary substance 
for use by man to supplement the diet by increasing the 
total daily intake, or a concentrate, metabolite, constituent, 
extract, or combinations of these ingredients 
• is intended for ingestion in pill, capsule, tablet, or liquid 
form. 
• is not represented for use as a conventional food or as the 
sole item of a meal or diet. 
• is labeled as a “dietary supplement.” 
• includes products such as an approved new drug, certified 
 
 24 Sloane, supra note 9, at 326. 
 25 Laura A. Khatcheressian, Regulation of Dietary Supplements: Five Years of DSHEA, 
54 FOOD & DRUG L.J. 623, 626 (1999). 
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antibiotic, or licensed biologic that was marketed as a 
dietary supplement or food before approval, certification, 
or license (unless the Secretary of Health and Human 
Services waives this provision).26 
Under the DSHEA, a dietary supplement is “adulterated” if it 
falls under any one of three new standards.27  First, the DSHEA deems 
a dietary supplement “adulterated” if any of its ingredients or the 
supplement itself present “a significant or unreasonable risk of illness 
or injury” when taken according to the directions on the label or 
under normal use when no directions are provided.28  Second, if a 
dietary supplement “pose[s] an imminent hazard to public health or 
safety,” the DSHEA deems this product adulterated and allows the 
Secretary of Health and Human Services (“Secretary”) to remove the 
supplement from the market.29  Lastly, if a dietary supplement 
contains a “new dietary ingredient,”30 it is considered adulterated if 
there exists insufficient information to reasonably assure the absence 
of a “significant or unreasonable risk.”31 
The DSHEA defines a “new dietary ingredient” as an “ingredient 
that was not marketed in the United States before October 15, 
1994.”32  The DSHEA’s definition of “new” suggests that it excludes 
dietary ingredients sold before October 15, 1994, even if marketed 
for a different use.33  If a manufacturer plans to sell a product 
containing a “new dietary ingredient,” it must give the FDA seventy-
five days notice and include information demonstrating that the 
 
 26 U.S. Food and Drug Administration Center for Food Safety and Applied 
Nutrition, Dietary Supplement Health and Education Act of 1994, at http://vm.cfsan.fda.g 
ov/~dms/dietsupp.html (Dec. 1, 1995) (on file with author) [hereinafter DSHEA 
Website].  The exact statutory language is found in 21 U.S.C. section 321(ff).  See 21 
U.S.C. § 321(ff) (2002). 
 27 Meghan Colloton, Dietary Supplements: A Challenge Facing the FDA in Mad Cow 
Disease Prevention, 51 AM. U. L. REV. 495, 526 (2002) (citing Dietary Supplement 
Health and Education Act of 1994, Pub. L. No. 103-417, sec. 4, § 402(f), 108 Stat. 
4325, 4328 (1994)); see also 21 U.S.C. § 342(f) (2002). 
 28 DSHEA Website, supra note 26; see also 21 U.S.C. § 342(f)(1)(A) (2002). 
 29 Colloton, supra note 27, at 526 (quoting Dietary Supplement Health and 
Education Act of 1994, Pub. L. No. 103-417, sec. 4, § 402(f)(1)(C), 108 Stat. 4325, 
4328 (1994)); see also 21 U.S.C. § 342(f)(1)(C) (2002). 
 30 21 U.S.C. § 350b(c) (1999).  A “new dietary ingredient” is an ingredient that 
was not present in a dietary supplement prior to October 15, 1994.  Id. 
 31 Colloton, supra note 27, at 526; see also 21 U.S.C. § 342(f)(1)(B) (2002). 
 32 Stephen H. McNamara & A. Wes Seigner, Jr., FDA has Substantial and Sufficient 
Authority to Regulate Dietary Supplements, 57 FOOD & DRUG L.J. 15, 20 (2002) (quoting 
21 U.S.C. § 350b(c) (1999) (F.D.C.A. Subchapter IV)). 
 33 Margaret Gilhooley, Deregulation and the Administrative Role: Looking at Dietary 
Supplements, 62 MONT. L. REV. 85, 119 (2001). 
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ingredient can “reasonably be expected to be safe.”34  The law does 
not, however, require FDA approval.35  Because there is no official 
record of ingredients that were sold before October 15, 1994, the 
manufacturer must determine whether a particular ingredient is 
“new.”36  In addition, a dietary supplement is deemed adulterated if it 
“is or contains a dietary ingredient that renders it adulterated under 
paragraph (a)(1) under the conditions of use recommended or 
suggested in the labeling of such dietary supplement.”37 
The FDA only has the power to limit the use of a specific dietary 
supplement (provided there is no “new” ingredient) if the FDA 
proves the supplement creates a “significant or unreasonable risk” 
under the dosage specified on the label.38  Therefore, provided the 
supplement does not contain a new ingredient, the FDA has no 
power to stop a dietary supplement from placement on the market.39  
These supplements will be available to consumers until the FDA 
shows that the supplement is a “significant or unreasonable risk,” 
typically established by adverse event reports.40 
An adverse event is an event that may be linked to a product or 
ingredient.41  The FDA has a system in effect to collect and review 
adverse event reports linked to dietary supplements.42  Reporting 
these adverse events is completely voluntary, and these adverse events 
are reported by “consumers, health professionals, and manufacturers 
through a variety of sources, including State health departments, 
Poison Control Centers, direct communication with individuals, and 
MedWatch, a computerized reporting system used to monitor a 
variety of FDA-regulated products.”43  In effect, the statute provides 
little protection to consumers until actual instances of harm have 
 
 34 DSHEA Website, supra note 26. 
 35 Ilene Ringel Heller, Functional Foods, Regulatory and Marketing Developments, 56 
FOOD & DRUG L.J. 197, 198-99 (2001). 
 36 See id. 
 37 21 U.S.C. § 342(f)(1)(D) (2002).  21 U.S.C. section 342(a)(1) 
addresses particular circumstances in which a food will be deemed 
adulterated.  See 21 U.S.C. § 342(a)(1) (2002).  For example, it states that a 
food is deemed adulterated if it “bears or contains any poisonous or 
deleterious substance which may render it injurious to health” or if it 
“consists in whole or in part of any filthy, putrid, or decomposed substance, 
or if it is otherwise unfit for food.”  Id. 
 38 21 U.S.C. § 342(f) (2002). 
 39 See id. 
 40 Colloton, supra note 27, at 529-30. 
 41 HHS Report, supra note 2, at 1. 
 42 Id. 
 43 Id. 
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occurred or until a basis exists to project that actual instances of 
harm will occur.44  Additionally, the DSHEA placed the burden of 
proving a supplement unsafe or adulterated on the FDA.45  With this 
lax statutory regime, potentially dangerous supplements are widely 
available to the public.46  These supplements may have serious side 
effects and may interact with other medications.47  For example, 
ginkgo biloba, a dietary supplement, is a blood thinner that may 
cause excessive bleeding, and may lead to stroke.48 
 
 44 21 U.S.C. § 342(f) (2002); see also Colloton, supra note 27, at 528-34. 
 45 Colloton, supra note 27, at 527. 
 46 See Colloton, supra note 27, at 497.  Some of the potential dangers of 
dietary supplements are worth noting to demonstrate the need for stricter 
regulation.  Ginkgo biloba, a popular herbal supplement, can cause 
excessive bleeding.  Levin, supra note 1.  Ginkgo biloba is sold in varying 
contents and amounts of active ingredients; to date, there is no specific daily 
amount established as safe.  NIH News Release, NIH Awards Multicenter Study 
on Ginkgo Biloba for Dementia, at http://www.nih.gov/news/pr/sept99/ncca 
m-30.htm (Sept. 30, 1999) (on file with author).  “Some recent cases imply 
that daily use of gingko biloba extracts may cause side effects, such as 
excessive bleeding, especially when combined with daily use of aspirin.”  Id.  
There is an additional risk in taking ginkgo biloba with anticoagulants and 
antiplatelet medications.  Melanie Johns Cupp, Herbal Remedies: Adverse Effects 
and Drug Interactions, AM. FAM. PHYSICIAN (Mar. 1, 1999), available at 
http://www.aafp.org/afp/990301ap/ 1239.html (on file with author). 
There are dangers even in conventional dietary supplements such as vitamin A. 
See Levin, supra note 1; see also Associated Press, Vitamin A linked to hip fracture, 
available at http://www.msnbc.com/news/680496.asp (Jan. 1, 1999) (on file with 
author).  High doses of vitamin A have been linked to birth defects, and recently 
have been associated with hip fractures.  Id.  Garlic may dangerously interfere with 
AIDS drugs. Associated Press, Garlic Pills may block AIDS drugs, available at www.msnb 
c.com/news/668796.asp (Dec. 6, 2001) (on file with author). 
Ephedra is a popular dietary supplement that is taken by approximately 12 
million Americans.  Stenson, supra note 4.  Ephedra is associated with cardiovascular 
problems such as high blood pressure, strokes, and heart attacks, in addition to 
being associated with seizures.  Id.  Furthermore, Ephedra has caused 20-30 deaths.  
Levin, supra note 1. 
St. John’s Wort should be avoided by individuals taking antidepressants.  Cupp, 
supra note 46.  Additionally, St. John’s Wort can interfere with oral birth control pills, 
AIDS drugs, cancer drugs, and treatments to help with organ transplants.  Stenson, 
supra note 4. 
Taking ginseng can cause a decreased response to warfarin, commonly known 
by its brand name, Coumadin.  Cupp, supra note 46.  Warfarin is generally prescribed 
to prevent the formation or movement of blood clots.  See http://www.fyipharmacist. 
com/monographs/coumadin.html (last visited Apr. 9, 2002) (on file with author). 
It has not yet been proven, but doctors caution that Androstendione may cause 
side effects similar to those of steroids, such as liver cancer.  Crossman, infra note 
196, at 632.  Creatine, when taken regularly, is presumed by some physicians to cause 
renal failure.  Id.  The preceding is just an abbreviated list of the potential hazards of 
dietary supplements. 
 47 See supra note 46 (describing potential side effects of dietary supplements). 
 48 HHS Report, supra note 2, at 7. 
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With the exception of new dietary ingredients, manufacturers 
have no obligation to provide the FDA with any evidence to prove the 
safety or efficacy of their product.49  Additionally, manufacturers are 
not required to register their product or company information with 
the FDA.50 
Presently, there are no FDA regulations that govern the 
manufacture of dietary supplements.51  The nature of some herbs 
makes the absence of FDA regulation especially dangerous.52  The 
potency of an herb depends on many different factors, such as soil, 
sunlight, temperature, season, age and structure of the plant, and the 
post-harvesting method used.53  Because of these factors, herbal 
remedies can differ significantly in quality and strength of 
ingredients.54  Herbal remedies frequently contain amounts of 
ingredients that differ, sometimes significantly, from the amount 
listed on the label.55 
The DSHEA gave the Secretary power to enact regulations that 
impose good manufacturing practices on dietary supplement 
manufacturers.56  The FDA plans to create these “good 
manufacturing practices” (“GMPs”) regulations for the dietary 
supplement industry.57  These regulations would work to ensure the 
“identity, purity, quality, strength and composition of dietary 
supplements.”58  Accordingly, the regulations should help prevent 
some of the dangers associated with dietary supplements, such as 
when prescription medications are illegally added into the 
supplements, or when supplements are contaminated with metals 
and pesticides.59  Additionally, GMPs would allow the FDA to confirm 
ingredient amounts contained in the product.60  Until the FDA issues 
 
 49 U.S. Food and Drug Administration Center for Food Safety and Applied 
Nutrition, Overview of Dietary Supplements, at http://vm.cfsan.fda.gov/~dms/ds-
oview.html#what (Jan. 3, 2001) (on file with author) [hereinafter FDA Overview 
Website]. 
 50 Id. 
 51 FDA Overview Website, supra note 49. 
 52 See Linda G. Tolstoi, Herbal Remedies: Buyer Beware, NUTRITION TODAY, July 2001, 
available at http://www.findarticles.com/cf_0/m0841/4_36/77841951/p1/article.jht 
ml?trm=Tolstoi (on file with author). 
 53 Id. 
 54 Id. 
 55 Stenson, supra note 4. 
 56 21 U.S.C. § 342 (g)(2) (2002). 
 57 FDA Overview Website, supra note 49. 
 58 Id. 
 59 See Stenson, supra note 4; see also HHS Report, supra note 2, at 23. 
 60 HHS Report, supra note 2, at 23. 
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these regulations, the manufacturer will continue to have power over 
its own production of dietary supplements.61 
B.  FDA’s Supervision of the Dietary Supplement Industry 
The DSHEA places dietary supplements within the food category 
and the FDA’s Center for Food Safety and Applied Nutrition 
(“CFSAN”) is responsible for the oversight of dietary supplements.62  
To police the dietary supplement market for illegal products, the 
FDA utilizes the Internet, results from inspections conducted on the 
manufacturers and distributors, complaints and adverse events 
reported to the FDA, and the occasional product laboratory test.63  
The FDA considers a product illegal when it exhibits false or 
misleading claims, or when the product is deemed unsafe.64 
Because manufacturers are generally not required to get FDA 
approval, nor are they required to register their products with the 
FDA, the FDA does not have a record of the supplements presently 
on the market.65  If a consumer desires more information on a 
particular product on the market, the FDA will not possess it.66  To 
obtain this additional information, the consumer must turn to the 
product manufacturer.67 
A recent U.S. Department of Health and Human Services 
(“HHS”) study concluded that the FDA’s method of supervision 
regarding dietary supplements is inadequate.68  The report stated that 
the FDA learns of less than one percent of the adverse events linked 
to dietary supplement use.69  The study opined that this low number 
 
 61 See FDA Overview Website, supra note 49.  21 C.F.R., pt. 111 is titled 
“CURRENT GOOD MANUFACTURING PRACTICE FOR DIETARY 
SUPPLEMENTS” and states that its authority comes from 21 U.S.C. sections 321, 342 
(2002), and 371 (1999).  21 C.F.R., pt. 111 (2002).  As of yet, there appears to be 
only one provision in this part, and it addresses the packaging of iron-containing 
dietary supplements.  See 21 C.F.R. § 111.50 (2002).  This section establishes that for 
certain iron-containing supplements to be in accordance with good manufacturing 
practices, the supplements must be in unit-dose packaging.  Id.  The provision goes 
on to define “unit-dose packaging,” and to exempt certain classes of iron-containing 
supplements.  Id. 
 62 FDA Overview Website, supra note 49. 
 63 Id. 
 64 Id. 
 65 Id. 
 66 Id. 
 67 Id. 
 68 EXECUTIVE BRIEFING, BNA’S HEALTH CARE DAILY REPORT (Apr. 24, 2001) 
[hereinafter EXECUTIVE BRIEFING]; see also HHS Report, supra note 2. 
 69 HHS Report, supra note 2. 
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may be due to various factors.70  The study noted, for example, that 
consumers may presume dietary supplements are safe, and, 
additionally, that consumers often take supplements without medical 
supervision.71  The report observed that the FDA was unsuccessful in 
obtaining the necessary information to properly look into the adverse 
events reported.72  For example, in the period between 1994 and 
1999, the FDA failed to obtain medical records for fifty-eight percent 
of the adverse event reports it was to investigate.73  The report listed 
other factors that illustrate how the oversight is inadequate, including 
the FDA’s inability to identify the ingredients in thirty-two percent of 
the supplements involved in the adverse event reports, the FDA’s 
failure to possess labels for seventy-seven percent of the supplements 
referred to in the reports, and the FDA’s failure to obtain sixty-nine 
percent of the supplement samples it requested from 
manufacturers.74  The report also criticized the use of the FDA’s 
website as its principal means for disseminating information to 
consumers.75  Among the reasons for this criticism was the fact that 
the FDA seldom updates the website and, therefore, the information 
contained in the website may be outdated.76 
C.  Overview of Permissible Claims Under DSHEA 
The DSHEA also addresses the claims that dietary supplement 
manufacturers place on their products.77  The statute clarifies what 
types of claims are permissible for dietary supplement labels.78  This 
comment gives only a broad overview of the DSHEA’s restrictions on 
permissible claims; however, it is important to address the permissible 
claims because the DSHEA arguably allows manufacturers to 
dangerously lead consumers to believe a certain dietary supplement 
will, for example, help treat a certain disease.79  The DSHEA does 
permit various statements to be placed on dietary supplement labels, 
 
 70 Id. 
 71 Id. 
 72 EXECUTIVE BRIEFING, supra note 68. 
 73 HHS Report, supra note 2. 
 74 Id. 
 75 Id. at 17. 
 76 EXECUTIVE BRIEFING, supra note 68. 
 77 Khatcheressian, supra note 25, at 628.  Claims are the statements 
manufacturers place on the labels of dietary supplements.  See DSHEA Website, supra 
note 26. 
 78 Kelly Ann Kaczka, From Herbal Prozac to Mark McGwire’s Tonic: How the Dietary 
Supplement Health and Education Act Changed the Regulatory Landscape for Health 
Products, 16 J. CONTEMP. HEALTH L. & POL’Y 463, 477-78 (2000). 
 79 Khatcheressian, supra note 25, at 637-38. 
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however, it does not allow these claims to state that the dietary 
supplement will “diagnose, prevent, mitigate, treat, or cure a specific 
disease (unless approved under the new drug provisions of the 
[Federal Food, Drug, and Cosmetic] Act).”80  There are three basic 
types of claims that are legally permissible: “health claims, 
structure/function claims, and nutrient content claims.”81  Different 
claims have different requirements.82  Prior regulations allowed 
health claims and nutrient content claims; the DSHEA added the 
category of structure/function claims.83 
The DSHEA permits claims asserting that a “dietary ingredient” 
impacts “the structure or function of the body” (“structure/function 
claims”).84  A permissible type of structure/function claim describes 
the “general well-being from consumption of a nutrient or dietary 
ingredient.”85  Another generally acceptable type of 
structure/function claim involves assertions that dietary supplement 
use is beneficial to a nutrient deficiency disease.86  Manufacturers 
have the responsibility of substantiating these structure/function 
claims; however, prior approval by the FDA is not required.87  The 
DSHEA does not define “substantiation,” and does not require 
submission to the FDA.88  When making structure/function claims, 
manufacturers need only include the following disclaimer on the 
 
 80 DSHEA Website, supra note 26. 
 81 U.S. Food and Drug Administration, Center for Food Safety and Applied 
Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements, Claims 
that Can be Made for Conventional Foods and Dietary Supplements, at http://www.cfsan.fd 
a.gov/~dms/hclaims.html (last revised Oct. 2001) (on file with author) [hereinafter 
FDA Claims Website]. 
 82 FDA Overview Website, supra note 49. 
 83 See FDA Claims Website, supra note 81. 
 84 Gilhooley, supra note 33, at 95-96 (citing 21 U.S.C. § 343(r)(6)(A) (2002)); see 
also 21 C.F.R. § 101.93 (2001).  21 C.F.R. section 101.93(f) states that dietary 
supplement labels may contain statements that “describe the role of a nutrient or 
dietary ingredient intended to affect the structure or function in humans or that 
characterize the documented mechanism by which a nutrient or dietary ingredient 
acts to maintain such structure or function.”  21 C.F.R. § 101.93(f) (2001).  This 
provision specifies that dietary supplement labels cannot make disease claims, as 
defined by 21 C.F.R. section 101.93(g), and if such claims are made, the product will 
be regulated as a drug.  Id. 
 85 Khatcheressian, supra note 25, at 628 (citing 21 U.S.C. § 343(r)(6) (2002)); see 
also FDA Claims Website, supra note 81 (listing this type of claim as allowed under 
the category of structure/function claims). 
 86 Khatcheressian, supra note 25, at 628; see also FDA Claims Website, supra note 
81.  If making such a claim, however, a manufacturer must include information on 
how prevalent this deficiency disease is in the United States.  FDA Claims Website, 
supra note 81. 
 87 Gilhooley, supra note 33, at 95; see also FDA Claims Website, supra note 81. 
 88 Khatcheressian, supra note 25, at 628. 
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label of the dietary supplement: “This statement has not been 
evaluated by the Food and Drug Administration.  This product is not 
intended to diagnose, treat, cure, or prevent any disease.”89  However, 
“[t]his system allows manufacturers of dietary supplements to hint 
that a product will help a disease without actually saying so (e.g., 
‘lowers cholesterol’ is reasonably understood by consumers to mean 
that the product treats the illness of high cholesterol).”90 
Health claims are also permissible.91  These claims “describe a 
relationship between a food substance and a disease or health-related 
condition.”92  There are two different avenues under which the FDA 
evaluates these claims to determine whether they are permissible.93  
Under the first avenue, the FDA reviews scientific literature.94  Here, 
if the FDA finds “significant scientific agreement” as to the particular 
nutrient/disease relationship, the claim is allowed.95  If there is 
insufficient scientific evidence to obtain permission through the first 
avenue, a second avenue is available to obtain this permission.96  The 
second avenue requires the FDA to “allow appropriately qualified 
health claims that would be misleading without such qualifications.”97  
These claims need only have sufficient scientific evidence such that 
there is more proof for the relationship than against it.98  The United 
States Circuit Court for the District of Columbia approved this 
second means of evaluating a claim in Pierson v. Shalala,99 in a 
decision “relating to supplements on constitutional grounds based on 
commercial free speech.”100 
D.  Research Efforts 
The DSHEA provided that the HHS Secretary should create an 
Office of Dietary Supplements (“ODS”).101  The DSHEA mandated 
the formation of the ODS to establish a body in charge of obtaining 
 
 89 Id. (quoting 21 U.S.C. § 343(r)(6)(C)); see also FDA Claims Website, supra note 
81. 
 90 Khatcheressian, supra note 25, at 637-38. 
 91 FDA Claims Website, supra note 81. 
 92 Id. 
 93 Id. 
 94 Id. 
 95 Id. 
 96 Id. 
 97 FDA Claims Website, supra note 81. 
 98 Id. 
 99 164 F.3d 650, 657 (D.C. Cir. 1999). 
 100 Gilhooley, supra note 33, at 110. 
 101 Sloane, supra note 9, at 328. 
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information on dietary supplements through scientific research and 
to subsequently distribute the information.102  On November 27, 1995, 
the ODS was formally established within the National Institutes of 
Health (“NIH”).103  The two primary goals of the ODS are: “(1) to 
research how dietary supplements can improve our nation’s 
healthcare system; and (2) to encourage the study of dietary 
supplements.”104  The ODS is also responsible for advising federal 
agencies on dietary supplement matters.105  The ODS, however, has 
no role in the regulation of dietary supplements.106 
At the start of 2000, the FDA announced its Ten Year Plan 
setting forth the CFSAN’s “overall dietary supplement strategy.”107  
Section V of this Ten Year Plan set forth CFSAN’s goals in science 
and research.108  In an effort to initiate these objectives, the FDA 
presented a two-year, $1 million grant to the National Academy of 
Sciences for the purpose of creating a framework for evaluating 
 
 102 Id. at 328, 337. 
 103 National Institutes of Health Office of Dietary Supplements, About ODS, at 
http://ods.od.nih.gov/about/started.html (last visited Oct. 20, 2002) (on file with 
author).  Specifically, the ODS was established “within the Office of Disease 
Prevention, Office of the Director, at the National Institutes of Health. Bernadette 
M. Marriott, Ph.D. was appointed Director of the ODS. The current Director is Paul 
M. Coates, Ph.D.”  Id. 
 104 Sloane, supra note 9, at 328. 
 105 Id. 
 106 Id. at 337. 
 107 LETTER FROM DIRECTOR, U.S. FOOD AND DRUG ADMINISTRATION, CENTER FOR 
FOOD SAFETY AND APPLIED NUTRITION, DIETARY SUPPLEMENT STRATEGY (TEN YEAR PLAN) 
(Jan. 2000), available at http://vm.cfsan.fda.gov/~dms/ds-strat.html (on file with 
author) [hereinafter TEN YEAR PLAN].  “The Center for Food Safety and Applied 
Nutrition, known as CFSAN, is one of six product-oriented centers, in addition to a 
nationwide field force, that carry out the mission of the Food and Drug 
Administration (FDA).”  U.S. Food and Drug Administration, Center for Food Safety 
and Applied Nutrition, Center for Food Safety and Applied Nutrition Overview, at 
http://www.cfsan.fda.gov/~lrd/cfs an.html (last updated Aug. 15, 2001) (on file with 
author).  “CFSAN, in conjunction with the Agency’s field staff, is responsible for 
promoting and protecting the public’s health by ensuring that the nation’s food 
supply is safe, sanitary, wholesome, and honestly labeled, and that cosmetic products 
are safe and properly labeled.”  Id. 
 108 Id.  One of the goals set out by Section V is to “enhance research/science 
capabilities,” including strengthening the science base by ensuing “sound science-
based program for all dietary supplement review and develop a core of well-trained, 
multidisciplinary scientists in support of supplement review and research.”  Id.  
Another goal mentioned in Section V is strengthening research efforts by working 
with the “assistance of a nationally recognized organization” to create a “broad 
research agenda and needs assessment framework to implement priority-based 
research for dietary supplement issues.”  Id.  Section V additionally sets out the goals 
related to, among other things, dietary supplement ingredient reviews, consumer 
research, marketplace research, and the adverse event monitoring system.  Id. 
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herbs.109 
More recently, on July 25, 2002, the National Institute of 
Environmental Health Sciences (“NIEHS”) and the ODS, both part 
of the NIH, announced a $6 million, five-year grant to create a 
research center to study Echinacea and Hypericum, known as St. 
John’s Wort.110  Echinacea and Hypericum are botanical dietary 
supplements.111  This new center, along with established NIH centers 
located at universities around the country, “[is] expected to greatly 
advance the scientific base of knowledge on botanicals, including 
issues of their effectiveness, safety, and biological action.”112 
II.  SPECIAL SITUATIONS LIMITING SCOPE OF DIETARY SUPPLEMENTS 
This section will focus on two recent court decisions: United States 
v. Undetermined Quantities of Articles of Drug113 and Pharmanex v. 
Shalala.114  In both of these cases, the courts had the power to evaluate 
the FDA’s interpretation and application of law, with the potential to 
either reduce or increase the FDA’s authority.115  Both courts ruled in 
favor of the FDA.116  These cases expanded the FDA’s power by 
allowing increased control, at least in these special circumstances, 
over dietary supplements.117  In these special cases, the court accepted 
an FDA position narrowing the meaning of “dietary supplement,” 
thereby promoting safety.118 
There is a great deal of controversy concerning products that 
claim to be dietary supplements while advertising that they act as 
natural alternatives to illicit drugs.119  In Undetermined Quantities,120 for 
example, some of the products at issue were called “Rave X,” 
 
 109 Stenson, supra note 4. 
 110 NIH News Release, NIH Funds Botanical Center in Iowa to Study Health Effects of 
Echinacea and St. John’s Wort, at http://www.nih.gov/news/pr/jul2002/niehs-25.htm 
(July 25, 2002) (on file with author). 
 111 Id. 
 112 Id. 
 113 145 F. Supp. 2d 692 (D. Md. 2001). 
 114 221 F.3d 1151 (10th Cir. 2000). 
 115 See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d 1151. 
 116 See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d 1151. 
 117 See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d 1151. 
 118 See Undetermined Quantities, 145 F. Supp. 2d 692; Pharmanex, 221 F.3d at 1151. 
 119 See, e.g., Cary Elizabeth Zuk, Herbal Remedies are Not Dietary Supplements: A 
Proposal for Regulatory Reform, 11 HASTINGS WOMEN’S L.J. 29, 43-46 (2000) (describing 
the marketing of, and the FDA’s reaction to, a product called “Herbal Ecstasy,” and 
its claims of, among other things, “euphoria, increased sexual sensations, [and] 
heightened awareness”). 
 120 Undetermined Quantities, 145 F. Supp. 2d at 696. 
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“Hashanna Oil,” “Herbal Hash,” and “Herbal Opium.”121  The 
defendants claimed these products were dietary supplements.122  The 
FDA disagreed, categorizing these products as “street drug 
alternatives,” and concluded that they were misbranded and 
unapproved drugs.123  This characterization meant the products were 
illegal as violative of the Food, Drug, & Cosmetic Act (“FDCA”).124  
The FDA seized the products and the Unites States brought action to 
seek an order of condemnation as well as permanent injunctive 
relief.125  The FDA relied on its own “Guidance for Industry on Street 
Drug Alternatives” (“the Guidance”)126 in making its determination.127  
The Guidance declared that these street drug alternatives were not 
dietary supplements, but instead were unapproved new and 
misbranded drugs.128  The Undetermined Quantities court agreed with 
the defendants that the Guidance was not binding because it was not 
a substantive rule, but rather an interpretive statement of the FDA’s 
position.129  Yet, the court did acknowledge that the Guidance was to 
be accorded some deference.130  The court noted that interpretations 
are entitled to some deference in the respect that they have the 
“power to persuade.”131  The court found that the Guidance was 
“highly persuasive in light of the text and purposes of the FDCA.”132  
The court refused “to carve out a statutory loophole for drug 
manufacturers attempting to profit from the illegal drug epidemic by 
 
 121 Id. 
 122 Id. 
 123 Id. 
 124 Id. 
 125 Id. 
 126 Guidance for Industry on Steet Drug Alternatives; Availability, 65 Fed. Reg. 17, 
512 (Dep’t of Health and Human Servs., FDA Apr. 3, 2000).  This guidance, in 
pertinent part, stated the following: 
[t]his guidance is intended to inform industry and the public that FDA 
considers any product that is promoted as a street drug alternative to 
be an unapproved new drug and a misbranded drug in violation of 
sections 505 and 502 of the act (21 U.S.C. §§ 355, 352).  Such violations 
may result in regulatory action, including seizure and injunction.  
Moreover, FDA is also aware that some of these street drug alternatives 
are being promoted as dietary supplements.  FDA does not consider 
street drug alternatives to be dietary supplements because they are not 
intended to supplement the diet. 
Id. 
 127 Id. 
 128 Undetermined Quantities, 145 F. Supp. 2d at 697. 
 129 Id. 
 130 Id. 
 131 Id. 
 132 Id. 
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masquerading potentially dangerous substances as legitimate dietary 
supplements.”133  The court noted that the definition of “dietary 
supplement” requires that the product be labeled as a dietary 
supplement.134  Because many of the defendants’ products at issue 
were not labeled as dietary supplements, they could not be regarded 
as dietary supplements.135  The court continued its analysis, however, 
to determine whether both these supplements, as well as those 
labeled as dietary supplements, fit within the definition of “drug.”136  
The court found that the term “drug” is defined by the FDCA as 
“articles (other than food) intended to affect the structure or any 
function of the body of man or other animals.”137  Therefore, the 
court posited, to be a “drug,” the product must both actually and 
intentionally “affect the structure or any function of the body.”138  In 
determining whether a product intends to have such an effect, the 
court emphasized that it is crucial to look at the claims and labeling 
made by the manufacturer.139  The court asserted that the products in 
question did purport to affect the mind.140  Concluding that the 
products intended “to affect the function and structure of the mind 
by elevating the psychological condition of users and therefore the 
products were ‘drugs,’”141  the court granted summary judgment to 
the government and ruled that these “street drug alternatives” were 
in fact new drugs in violation of the FDCA.142  The court recognized 
the danger of manufacturers attempting to classify products as dietary 
supplements.143  Manufacturers would presumably want their 
products to be classified as dietary supplements, as in the present 
case, because of the relaxed regulations.144  Fortunately, the court 
stepped in and disallowed the manufacturers from taking advantage 
of the DSHEA’s loose requirements.145 
 
 133 Id. 
 134 Undetermined Quantities, 145 F. Supp. 2d at 698. 
 135 Id. 
 136 See id.  In United States v. Ten Cartons, the court ruled that a particular product 
can qualify both as a “dietary supplement” and as a “drug.”  72 F.3d 285 (2d Cir. 
1995). 
 137 Undetermined Quantities, 145 F. Supp. 2d at 698 (citing 21 U.S.C. § 
321(g)(1)(C)). 
 138 Id. 
 139 Id. 
 140 Id. 
 141 Id. at 700. 
 142 Id. at 692. 
 143 See Undetermined Quantities, 145 F. Supp. 2d at 692. 
 144 Id. at 696-97. 
 145 See id. at 692. 
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This case demonstrates how courts can help to increase the 
FDA’s current power over dietary supplements.146  Interpretations can 
significantly affect regulatory policy,147 and in deferring to the FDA 
regarding their more expansive interpretations, courts may be able to 
assist in expanding power over the dietary supplement industry.  The 
court recognized the danger inherent in the defendants’ attempt to 
circumvent anti-drug laws and the FDCA, and appears to have 
reached its conclusion in part to prevent these potential dangers.148 
In Pharmanex,149 the plaintiff challenged the FDA’s interpretation 
of 21 U.S.C. §321(ff)(3)(B)—part of the FDCA as amended by the 
DSHEA—which defines the term “dietary supplement.”150  This 
statute states that the term “dietary supplement” does not include 
articles approved as new drugs.151  The FDA’s argument was that the 
statutory language stating, “an article that is approved as a new drug,” 
applies to both finished products and active ingredients.152  After 
analyzing Pharmanex’s argument that the plain meaning cannot 
support such an interpretation, looking at the legislative history, and 
examining the policies of the DSHEA and the FDCA, the court 
concluded that the language was “sufficiently ambiguous to merit 
Chevron deference.”153  The court, therefore, held that the FDA’s 
interpretation as applying to both active ingredients and to finished 
products was not “arbitrary, capricious, or manifestly contrary to the 
statute.”154 
This holding allowed the FDA to prevent Pharmanex from 
 
 146 See id. 
 147 Daniel B. Rodriquez, The Presumption of Reviewability: A Study in Canonical 
Construction and Its Consequences, 45 VAND. L. REV. 743, 766-67 (1992) (stating that 
“[b]y developing and applying the canons of construction, courts can recover from 
the political branches a certain amount of power over the process of interpretation 
and, as a consequence, preserve their role in implementing and making regulatory 
policy”). 
 148 See Undetermined Quantities, 145 F. Supp. 2d at 697. 
 149 Pharmanex v. Shalala, 221 F.3d 1151 (10th Cir. 2000). 
 150 Id. at 1153. 
 151 Id. at 1154. 
 152 Id. 
 153 Id.  The U.S. Supreme Court first articulated the Chevron deference test in 
Chevron U.S.A., Inc. v. Nat’l Res. Def. Council, 467 U.S. 837 (1984).  The Chevron Court 
set forth the standard to review an agency’s construction of a statute.  Id.  The first 
inquiry, in reviewing an agency’s construction of a statute, is whether “Congress has 
directly spoken to the precise question at issue.”  Id.  If the answer to this inquiry is 
yes, then Congress’s intent must prevail.  Id.  If, however, the answer to that inquiry is 
no, then the court must evaluate only whether “the agency’s answer is based on a 
permissible construction of the statute” in order to allow the agency’s interpretation 
to stand.  Id. 
 154 Pharmanex, 221 F.3d at 1160. 
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marketing its product as a dietary supplement without FDA approval 
because the supplement contained an active ingredient, mevinolin, 
which the FDA deemed to be a drug.155  This case illustrates the 
realistic danger that dietary supplement manufacturers may 
formulate products that are categorized as dietary supplements, yet 
imitate drugs—allowing manufacturers to avoid the stricter 
regulatory framework that applies to drugs.156  The FDA, as a result of 
this case, can look not only at finished products as a whole to 
determine their status as a dietary supplement, but also at individual 
ingredients within a product to see if any ingredients are properly 
characterized as drugs.157  This decision gives the FDA the authority to 
prevent manufacturers from placing substances that would be 
characterized as drugs if taken alone into a formula of other 
ingredients to gain the status and looser regulations of dietary 
supplements.158 
III.  THE ROLE OF THE STATES 
A.  State attempts to increase control over dietary supplements within 
their borders 
Some states have enacted statutes to increase control over a 
certain dietary supplement—ephedrine.159  This Comment addresses 
various legislative steps states have taken to protect their citizens from 
the harms presented by ephedrine.  These legislative steps include 
 
 155 Id. at 1153. 
 156 See Termini, supra note 13, at 287. 
 157 Pharmanex, 221 F.3d at 1153. 
 158 Id. 
 159 HHS Report, supra note 2, at 28.  A description of ephedra was given in the 
HHS Report, and stated that 
[e]phedrine alkaloids may be derived from plants (botanicals) or 
synthesized chemically.  The botanical form is generally derived from 
Ephedra sinica, also known as ma huang, but it may come from other 
botanical sources.  The most common uses for supplements containing 
botanical ephedrine alkaloids are for losing weight and boosting 
energy. . . .  According to the FDA, between 1993, when it began a new 
system to collect dietary supplement adverse event reports, and March, 
2000, it received 1,173 adverse event reports associated with the use of 
products that contain, or were suspected to contain, ephedrine 
alkaloids.  Many of these reports involved serious events, including 
some deaths. . . .  As of September 2000, FDA had not taken any action 
to regulate ephedrine alkaloids, although during this time period many 
States and industry groups have taken safety measures related to these 
supplements. 
Id. 
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making ephedrine available only by prescription, prohibiting any 
individual who is not a pharmacist from dispensing ephedrine, and 
making it a criminal offense to sell ephedrine-containing products to 
minors or individuals under seventeen years of age.160  For example, 
in Texas, a “person commits an offense if the person knowingly sells, 
transfers, or otherwise furnishes a product containing ephedrine to a 
person under 17 years of age,” with certain exceptions.161  Florida 
makes it necessary to obtain a prescription for products containing 
ephedrine.162  Tennessee, Louisiana, and Minnesota have statutes, 
which provide that ephedrine-based products “may be dispensed only 
upon prescription of a duly licensed practitioner authorized by the 
laws of the state to prescribe prescription drugs.”163  Ohio mandates 
that consumers obtain ephedrine substances from pharmacists only, 
with certain exceptions, and that consumers must be at least eighteen 
years of age.164  Virginia has a statute that makes it a Class 1 
misdemeanor to “knowingly sell or otherwise distribute (without 
prescription), to a minor, any pill, capsule, or tablet containing any 
combination of caffeine and ephedrine sulfate.”165  Nebraska statutory 
law imposes certain requirements for labeling on ephedrine 
containing food and dietary supplements, and requires that a 
 
 160 See, e.g., TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1 
(West 1995); MINN. STAT. ANN. § 152.135 (West 1998); TEX. HEALTH & SAFETY CODE 
ANN. § 431.022 (Vernon 2001); OHIO REV. CODE ANN. §§ 3719.41 (West 1999), 
3719.44(K)(1) (West 2002); VA. CODE ANN. §§ 18.2 – 248.5(B) (Michie 2000); NEB. 
REV. STAT. § 28-448 (2001). 
 161 TEX. HEALTH & SAFETY CODE ANN. § 431.022 (Vernon 2001).  The prohibition 
made in this statute does not apply if: 
(1) the actor is: (A) a practitioner or other health care provider 
licensed by this state who has obtained, as required by law, consent to 
the treatment of the person to whom the product is furnished; or (B) 
the parent, guardian, or managing conservator of the person to whom 
the product is furnished; (2) the person to whom the product is 
furnished has had the disabilities of minority removed for general 
purposes under Chapter 31, Family Code; or (3) the product is a drug. 
TEX. HEALTH & SAFETY CODE ANN. § 431.022 (Vernon 2001). 
 162 Jennifer Sardina, Note, Misconceptions and Misleading Information Prevail—Less 
Regulation Does Not Mean Less Danger to Consumers: Dangerous Herbal Weight Loss 
Products, 14 J.L. & HEALTH 107, 123-24 (2000). 
 163 TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1 (West 
1995); MINN. STAT. ANN. § 152.135 (West 1998). 
 164 Kaiser, supra note 15, at 1269; see also OHIO REV. CODE ANN. §§ 3719.41 (West 
1999), 3719.44(K)(1) (West 2002).  Ohio state law classifies ephedrine as a Schedule 
V drug, which requires a prescription, except as provided by § 3719.44(K)(1).  OHIO 
REV. CODE ANN. § 3719.41 (West 1999).  Section 3719.44(K)(1) lists specific products 
that are not to be considered schedule V drugs, such as amesec capsules, Primatene 
“M” and “P” formula tablets, and Vatronol nose drops.  Id. 
 165 VA. CODE ANN. §§ 18.2 – 248.5(B) (Michie 2000). 
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“prominent label securely affixed to each package” include certain 
specific information such as the amount of ephedrine in milligrams 
and a maximum dosage.166  Importantly, the statute also requires that 
this label contain a specific warning.167 
B.  Preemption 
In Jones v. Rath Packing Co.,168 the United States Supreme Court 
described preemption law as occurring: 
when Congress has “unmistakably . . . ordained,” that its 
enactments alone are to regulate a part of commerce, state laws 
regulating that aspect of commerce must fall.  This result is 
compelled whether Congress’ command is explicitly stated in the 
statute’s language or implicitly contained in its structure and 
purpose.169 
Therefore, preemption may be either express or implied.170  One type 
 
 166 NEB. REV. STAT. § 28-448 (2001). 
 167 Id.  The warning must state: 
WARNING: Not intended for use by anyone under the age of 18.  Do 
not use this product if you are pregnant or nursing.  Consult a health 
care professional before using this product if you have heart disease, 
thyroid disease, diabetes, high blood pressure, depression or other 
psychiatric condition, glaucoma, difficulty in urinating, prostate 
enlargement, or seizure disorder, if you are using a monoamine 
oxidase inhibitor (MAOI) or any other prescription drug, or if you are 
using an over-the-counter drug containing ephedrine, 
pseudoephedrine, or phenylpropanolamine (ingredients found in 
certain allergy, asthma, cough/cold, and weight control products).  
Discontinue use and call a health care professional immediately if you 
experience rapid heartbeat, dizziness, severe headache, shortness of 
breath, or other similar symptoms. 
Id. 
 168 430 U.S. 519 (1977). 
 169 Id. at 525. 
 170 Id.  A case on the October 2002 United States Supreme Court docket was 
expected to clarify the implied preemption doctrine.  Binh Ha Hong, Sprietsma, Rex 
v. Mercury Marine, at http://www.medill.nwu.edu/cases.srch?-database=docket&-
layout=lasso&-response=/docket/detail.srch&-search&docket=01-0706 (last visited 
Oct. 21, 2002) (on file with author).  The case, Sprietsma v. Mercury Maine, was 
decided on December 3, 2002.  123 S. Ct. 518 (2002).  The question at issue was 
“whether a state common-law tort action seeking damages from the manufacturer of 
an out-board motor is [preempted] either by the enactment of the Federal Boat 
Safety Act of 1971 [FBSA]” or by a 1990 Secretary of Transportation decision “not to 
promulgate a regulation requiring propeller guards on motor boats.”  Id. at 522.  
The United States Supreme Court rejected the argument that “a need for regulatory 
uniformity mandated a finding of federal preemption.”  Trial Lawyers for Public 
Justice, Supreme Court Holds that Injury Victims May Sue Boat Engine Manufacturers for 
Failure to Install Propeller Guards, at http://www.tlpj.org/pressreleases/sprietsma_12-
03-02.htm (last visited Jan. 26, 2003) (on file with author).  The Court, noting that 
the express preemption clause in the FBSA did not include common-law claims, 
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of implied preemption is field preemption.171  Field preemption exists 
where the federal regulation in an area is “so pervasive as to make 
reasonable the inference that Congress left no room for the states to 
supplement it.”172  The second type of implied pre-emption is conflict 
pre-emption.173  Conflict pre-emption is present when a state’s law 
“stands as an obstacle to the accomplishment and execution of the 
full purposes and objectives of Congress.”174 
The DSHEA does not contain a general preemption clause, and 
therefore, there is no express preemption.175  When analyzing the 
purposes of the enactment of the DSHEA, however, it is clear that the 
federal government wanted to make dietary supplements more 
accessible to consumers, and that Congress wanted the FDA to have 
the power to act against dangerous dietary supplements.176  State 
action that hinders consumers’ ability to access these supplements 
may be in opposition to the congressional objectives of availability, 
and accordingly, it may be possible that these actions are subject to 
preemption.177 
 
found that it “made sense for Congress not to [preempt] common-law claims, which 
necessarily perform an important remedial role in compensating accident victims.”  
Binh Ha Hong, Sprietsma Rex v. Mercury Maine, at http://journalism.medill.north 
western.edu/docket/action.lasso?-database=docket&-layout=lasso&-response=%2F 
docket%2Fdetail.srch&-recordID=33049&-search (last visited Jan. 26, 2003) (on file 
with author). 
 171 Gade v. Nat’l Solid Waste Mgmt. Ass’n, 505 U.S. 88 (1992). 
 172 Rice v. Santa Fe Elevator Corp., 331 U.S. 218, 230 (1947). 
 173 Gade, 505 U.S. 88. 
 174 Florida Lime & Avocado Growers, Inc. v. Paul, 373 U.S. 132, 142-43 (1963). 
 175 Pinco & Rubin, Ambiguities of the Dietary Supplement Health and Education Act of 
1994, 51 FOOD & DRUG L. J. 383, 397 (1996). 
 176 Id.; see also Dietary Supplement Health and Education Act of 1994, Pub. L. No. 
103-417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings). 
 177 Pinco & Rubin, supra note 175, at 397; see also Dietary Supplement Health 
and Education Act of 1994, Pub. L. No. 103-417, sec. 2, 108 Stat. 4325, 4326 
(Congressional Findings).  It is important to note that the federal government 
plans to mandate its own particular warning labels for ephedra products, 
thereby creating an even stronger preemption argument against state 
warning label legislation.  Ephedra: Government Urges Strongest Possible Warning 
Labels for Ephedra Products, 6 No. 4 ANDREWS DRUG RECALL LITIG. REP. 8 (Nov. 
2002).  “Following a flurry of lawsuits against manufacturers of ephedra-
based diet remedies and calls by consumer groups for tighter regulation of 
such products, the [HHS] has ordered the [FDA] to generate the ‘strongest 
possible mandatory warning label for ephedra products.’”  Id.  “Ephedrine, 
an adrenaline-like neurostimulator, is the active ingredient in ephedra.”  
Ephedra: Legal Troubles Mount for Maker of Ephedra Supplements, 18 No. 5 
ANDREWS PHARMACEUTICAL LITIG. REP. 7 (Sept. 2002). 
At present, there appear to be no federal regulations in direct conflict with the 
state provisions discussed in Part III.A.  There have been, however, attempts by the 
federal government to regulate ephedrine products.  See, e.g., Dietary Supplements 
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C.  Commerce Clause 
The Commerce Clause may prohibit state regulation.178  States, 
under their police powers, have the power to regulate intrastate 
commerce, even in a manner that will affect interstate commerce.179  
State legislation in this area must not, however, be protectionist in 
nature.180  When state legislation is aimed against interstate 
commerce, the court will apply a two-part test to determine whether 
 
Containing Ephedrine Alkaloids from Department of Health and Human Services, 
Food and Drug Administration, 65 Fed. Reg. 17474 (withdrawal in part April 3, 
2000).  On April 3, 2000, the FDA announced that it was withdrawing specific 
provisions of its proposed June 4, 1997 rule regarding dietary supplements that 
contain ephedrine alkaloids.  Id.  This action was prompted by the Government 
Accounting Office’s (GAO) concerns regarding the FDA’s basis for establishing the 
proposed dietary ingredient level and the limit on duration of use.  Id.  The June 4, 
1997 FDA proposed rule sought to establish when an ephedrine alkaloid containing 
a dietary supplement would be deemed adulterated.  Id.  The proposed FDA 
regulations were initiated “in response to reports of serious illnesses and injuries, 
including a number of deaths, associated with the use of dietary supplement 
products containing ephedrine alkaloids and the agency’s investigations and 
assessment of these illnesses and injuries.”  Id.  The GAO agreed with the FDA that 
attention and action against dietary supplements containing ephedrine alkaloids was 
appropriate.  Id.  The GAO, however, “expressed concerns about the use of the 
reported adverse events in supporting the proposed dosing level and duration of use 
limit, and concluded that the agency needed additional evidence to support these 
restrictions.”  Id.  The “GAO recommended that FDA ‘provide stronger evidence on 
the relationship between the intake of dietary supplements containing ephedrine 
alkaloids and the occurrence of adverse reactions that support the proposed dosing 
level and duration of use limits.’  In addition, GAO recommended that FDA improve 
the transparency of its cost-benefit analysis in its final rulemaking.”  Id.  These 
conclusions, in addition to other comments on the proposed rules, prompted the 
FDA to announce that certain aspects of the proposed rule should be reassessed.  Id.  
Therefore, the FDA withdrew the provisions of the proposed rule regarding the 
ingredient level and duration of use limits.  Id.  The FDA plans to reevaluate whether 
ingredient level and/or duration of use limits are appropriate, and will use public 
input to assist in these determinations.  Id.  The FDA did not withdraw the provisions 
concerning the “prohibition on the use of ingredients with stimulant effects with 
dietary supplements containing ephedrine alkaloids (§111.100(d)) and the proposed 
warning statement (§111.100(g)).”  Id.  The FDA did not at the time of this 
announcement conclude whether it will finalize these two provisions. 
 178 U.S. CONST. art. I, § 8, cl. 3 (Commerce Clause).  The Commerce Clause states 
that Congress has the power “to regulate commerce with foreign nations, and among 
the several States, and with the Indian tribes.”  Id. 
 179 See United Nuclear Corp. v. Gen. Atomic Co., 629 P.2d 231, 270 (N.M. 1980) 
(citing Merrill Lynch, Pierce, Fenner & Smith v. Ware, 414 U.S. 117, 140 (1973)); see 
also Cities Serv. Co. v. Peerless Co., 340 U.S. 179, 186 (1950); Southern Pac. Co. v. 
Arizona, 325 U.S. 761, 766-67 (1945); K.S.B. Tech. Sales v. North Jersey, 75 N.J. 272, 
381 A.2d 774 (N.J. 1977)). 
 180 Philadelphia v. New Jersey, 437 U.S. 617, 626-27 (1978).  The Court stated that 
if a state enacted a “law that overtly blocks the flow of interstate commerce at a 
State’s borders,” it would clearly be an example of economic protectionism.  Id. at 
624. 
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such legislation may be upheld.181  This test requires the court first to 
determine whether regulation’s “effects on interstate commerce are 
only incidental.”182  If the court determines that the effects are only 
incidental, the regulation will be valid as long as the burden it creates 
on interstate commerce is not “clearly excessive in relation to the 
putative local benefits.”183 
State imposition of prescription status for particular products 
may potentially create a burden on interstate commerce.  For 
example, granting products containing ephedrine prescription status 
would restrict the ability of manufacturers to legally sell those 
products to certain entities.184  A state’s interest in protecting the 
health of its citizens is a legitimate state interest.185  If a court finds the 
burdens imposed on interstate commerce are more than incidental, 
it will disallow the regulation.186  Conversely, the court applies the two-
 
 181 See On petition for Review of Opinion 475 of the Advisory Committee on 
Professional Ethics and DR 2102(C), 89 N.J. 74, 91,444 A.2d 1092, 1100 (N.J. 1982) 
(upholding “regulations whenever (1) they are rationally to legitimate state 
concerns, and (2) the resulting discrimination is outweighed by the state interest in 
enforcing the regulation”). 
 182 United Nuclear, 629 P.2d 270 (citing Pike v. Bruce Church, Inc., 397 U.S. 137, 
142 (1970)). 
 183 Id. 
 184 For example, in New Jersey, 
[n]o person, who is not a registered pharmacist or an apprentice 
employed in a pharmacy or drug store under the immediate personal 
supervision of a registered pharmacist, or who is not a duly licensed 
physician, dentist, veterinarian or other person licensed to prescribe 
drugs shall sell, dispense, or furnish any drug the label of which by law 
or regulations of the State Department of Health or Federal Food and 
Drug Administration is required to bear a statement that it is to be 
dispensed only by or on the prescription of a physician, dentist, 
veterinarian or other person licensed to prescribe drugs, or words of 
similar or like import; nor shall any registered pharmacist, or any 
apprentice employed in a pharmacy or drug store under the 
immediate personal supervision of a registered pharmacist, sell, 
dispense, or furnish any such drug except upon the prescription of a 
duly licensed physician, dentist, veterinarian or other person licensed 
to prescribe such drug. 
     . . . . 
The provisions of this act shall not apply to the sale of any such drug by 
a manufacturer or wholesaler or pharmacy to each other or to or by a 
physician, dentist, veterinarian or other person licensed to prescribe 
such drug in their professional practice. 
N.J. STAT. ANN. § 45:14-26.1 (West 1995). 
 185 See Hughes v. Oklahoma, 441 U.S. 322, 337 (1979) (“We consider the States’ 
interests in conservation and protection of wild animals as legitimate local purposes 
similar to the States’ interests in protecting the health and safety of their citizens.”). 
 186 See United Nuclear, 629 P.2d at 270 (citing Pike, 397 U.S. at 142). 
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step balancing test if the burden is only incidental.187 
Additionally, other state actions, such as Nebraska’s statute that 
requires specific warnings be affixed to labels, could be Commerce 
Clause violations.188  Separate labeling requirements imposed by 
individual states may effect interstate commerce in a way that is not 
merely incidental.  It potentially could be too costly and burdensome 
for manufacturers to meet each separate state’s labeling 
requirements.  Even if the court finds the burdens incidental, the 
balancing test must be applied and the possibility exists that the 
burdens would be found to outweigh the benefits of such 
regulations.189 
As addressed above, state regulation of dietary supplements may 
potentially create many problems.190  There may be preemption issues 
as well as possible Commerce Clause violations.191  Inconsistent 
standards across the country can interfere with a manufacturer’s 
ability to comply with all of them. 
IV.  ALTERNATIVES TO THE CURRENT DSHEA METHOD OF 
REGULATION 
The main problem with the current regulatory system is that 
dietary supplements that are not approved prior to marketing are 
readily available to consumers of all ages, despite the fact that they 
pose potential health risks.  Commentators have proposed numerous 
solutions to this problem, ranging from congressional action to 
stricter enforcement of the FDA’s goals and statutory regime.192  This 
section will address the strengths and weaknesses of some of those 
proposals, and will evaluate other possible solutions not yet proposed.  
Additionally, the FDA and other organizations are presently taking 
actions to fill some of the gaps that exist in dietary supplement 
regulation; this section will address those actions and assess their 
sufficiency. 
A.  Leaving the Present Scheme Unaltered 
One possibility is to leave the scheme as it presently stands, 
thereby encouraging states to continue to enact statutory law 
restricting the availability of certain dietary supplements within their 
 
 187 See id. 
 188 See NEB. REV. STAT. § 28-448 (2001). 
 189 See United Nuclear, 629 P.2d at 270. 
 190 See supra PART III.B-C. 
 191 See id. 
 192 See, e.g., infra notes 196, 207, and 218. 
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borders, if they desire a stricter scheme.  As of now, state action has 
been centered around restriction of, or total bans on, ephedrine and 
ephedrine products.193  Greater state regulation of dietary 
supplements, however, threatens to impinge on at least one of 
Congress’s goals in enacting the DSHEA—expanding availability.194  
States that choose to increase regulation in a manner that frustrates 
Congressional goals may face a preemption challenge.195 
B.  Pre-market Approval 
A second possible solution is to require pre-market approval of 
dietary supplements by requiring all manufacturers to submit 
evidence of the safety and efficacy of the product to the FDA prior to 
introducing it to the market, regardless of whether it has a “new 
ingredient.”196  This solution would require legislative changes to the 
present statute.197  This approach ensures the safety of dietary 
supplements by requiring proof of safety before marketing.198  The 
FDA would then have the opportunity to reject potentially dangerous 
supplements before consumers can ingest them, and manufacturers 
who know their products are unsafe would likely be reluctant to 
spend time and money to attempt to obtain FDA approval when such 
approval is unlikely.199  This approach, however, may run in direct 
opposition to the congressional goal of availability by imposing a 
regulatory barrier prior to marketing.200 
Requiring dietary supplement manufacturers to test products 
prior to marketing may create economic disincentives that discourage 
manufacturers from producing supplements.201  The testing and 
approval process is expensive, and FDA approval is a time consuming 
 
 193 See generally PART III.A. 
 194 See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-
417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings). 
 195 See PART III.B. 
 196 See Jeffrey A. Crossman, Note, “Sparing Cain: Executive Clemency in Capital Cases”: 
Mark McGwire Does It, So Why Can’t I? High School Student Use of Dietary Supplements and 
the Failure of the DSHEA, 28 CAP. U. L. REV. 617, 656 (2000) (suggesting that the FDA 
should have the power to subject dietary supplements to the same standards and 
requirements as are imposed on foods and drugs).  For an explanation of these 
requirements, see Crossman, supra, at 643-44. 
 197 See generally Dietary Supplement Health and Education Act of 1994, Pub. L. No. 
103-417, 108 Stat. 4325 (codified as amended in scattered sections of 21 U.S.C.). 
 198 See Crossman, supra note 196, at 643-44, 656. 
 199 See id. 
 200 See Dietary Supplement Health and Education Act of 1994, Pub. L. No. 103-
417, sec. 2, 108 Stat. 4325, 4326 (Congressional Findings). 
 201 See Kaiser, supra note 15, at 1260. 
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process.202  Drug manufacturers are economically capable of 
complying with pre-market clearance requirements because by 
patenting their drug they can secure income for profits and 
research.203  Herbal supplement manufacturers do not have the 
economic protection that a patenting system would afford, and 
accordingly, do not have the same financial capabilities to comply 
with pre-market clearance requirements as do drug manufacturers.204  
If a system of patenting could be fashioned for dietary supplements, it 
would give manufacturers an opportunity to recover the funds 
expended in initial testing for safety.205 
C.  Creating “New” Ingredient Lists 
One means by which the FDA could regain some control over 
what enters the market involves compiling a list of dietary ingredients 
that are not “new” within the relevant definition of the word.  It 
arguably should not be the manufacturer’s responsibility to 
determine whether its product contains a “new” ingredient, because 
the manufacturer has an interest in determining that the ingredients 
in their supplement are not in fact “new.”206  The FDA could compile 
this list and include all ingredients that the FDA would not consider 
“new,” thereby eliminating the manufacturer’s power to determine 
whether or not its product contains a “new” ingredient.  The FDA, 
however, may be better served expending its resources trying to find 
dangerous supplements, rather than by relieving manufacturers from 
the burden of making this determination. 
D.  Increasing Manufacturer Responsibilities 
An alternative solution involves a change in the reporting system 
that requires all dietary supplement manufacturers report to the FDA 
any side effects or adverse events linked to the use of a supplement.207  
If manufacturers informed the FDA of side effects and adverse events, 
 
 202 Id.  Manufacturers can expect to spend $2,000,000 on the process, and 
subsequently will have to wait two to six years to gain approval from the FDA.  Id. 
 203 Sonia Sequeira, Drug Rules Under Spotlight at WTO, at http://www.cnn.com/ 
2001/WORLD/europe/11/08/wto.trips/ (Nov. 8, 2001) (on file with author). 
 204 Zuk, supra note 119, at 38. 
 205 Schindler, supra note 14, at 279-80. 
 206 See DSHEA Website, supra note 26 (describing the additional requirements 
when introducing a “new dietary ingredient” to the market). 
 207 Robert Hager, Unsafe Supplements?, at http://www.msnbc.com/news/55761 
8.asp (Apr. 10, 2001) (on file with author).  In Appendix C of the HHS Report, the 
FDA noted that it is “evaluating whether or not such a reporting could be required 
under current law.”  HHS Report, supra note 2, at 41. 
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the FDA could evaluate the risks and alert consumers when 
necessary.208  This procedure is already required of pharmaceutical 
manufacturers; adverse events for prescription drugs and for some 
over-the-counter drugs must be reported.209  This would allow the 
FDA access to more information, and accordingly, would help the 
FDA inform consumers and act against unsafe supplements.210  It may 
be difficult, however, for the FDA to ensure manufacturers are 
complying with this reporting requirement.211 
Alternatively, the FDA could compel manufacturers to register 
the dietary supplements they place on the market.212  The 
implementation of such a registration requirement would necessitate 
a legislative change in the DSHEA, and the commitment of 
additional resources.213  Presently, the FDA has difficulty determining 
what ingredients are in each supplement,214 therefore, along with this 
registration, the manufacturer should be compelled to provide a list 
of all of the ingredients in the supplement.215  This could assist the 
FDA in following up on adverse reports.  When the FDA receives 
adverse reports, it would have the manufacturer’s name and contact 
information, along with the supplements it sells and the ingredients 
in each supplement.216  A registration system would give the FDA 
sufficient information to act quickly on adverse event reports.217 
E.  Germany’s Approval System 
At least one commentator has suggested establishing a system 
similar to that used in Germany.218  In Germany, prior to marketing 
an herbal remedy, safety and “reasonable proof” of efficacy of the 
 
 208 Id. 
 209 HHS Report, supra note 2, at 19. 
 210 See id. (suggesting a requirement that manufacturers report adverse events in 
order to “facilitate greater detection of adverse events”). 
 211 Id.  The HHS report goes on to suggest the FDA should convince 
manufacturers of the importance and adequacy of such a system in order to promote 
compliance.  Id. 
 212 Id. 
 213 Id. at 25. 
 214 EXECUTIVE BRIEFING, supra note 68. 
 215 Hager, supra note 207. 
 216 HHS Report, supra note 2, at 20-21. 
 217 See id. at 20 (noting that requiring “dietary supplement manufacturers to 
register their products with the FDA” would “improve the quality and quantity of . . . 
product information” and therefore “generate stronger signals of public health 
concerns”). 
 218 Stenson, supra note 4. 
 2003 COMMENT 439 
product must be established.219  Germany has an independent panel 
of medical experts with the responsibility of reviewing different 
herbal remedies and evaluating their efficacy and safety.220  This panel 
also has the responsibility of creating monographs for some of these 
herbal remedies.221  A product meets its burden of proof when the 
panel gives an indication in a monograph.222  This standard is not as 
stringent as the FDA’s standard for the entrance of drugs and food 
additives into the market.223  It does, however, impose some entrance 
requirements prior to marketing, unlike the current DSHEA 
regime.224 
F.  Changes in Enforcement 
Yet another improvement to the current system involves a 
change in enforcement.  As mentioned in Part I, the FDA often 
requests samples from manufacturers when investigating an adverse 
event report, and more often than not, manufacturers fail to 
comply.225  FDA sanctions for noncompliance would possibly enable 
the FDA to follow up on adverse event reports more efficiently and 
thoroughly.  This method would also give the FDA a greater ability to 
warn consumers of potentially harmful supplements on the market.  
Without imposing sanctions, the trend of manufacturers failing to 
comply with these requests may be difficult to change. 
G.  Additional Research 
Additional safety research on dietary supplements would likely 
help to improve the current system.226  If the FDA conducted its own 
studies, or funded independent studies, the results would increase 
the FDA’s access to information.227  This information could be used to 
“adequately assess signals generated by the adverse event reporting 
 
 219 Tolstoi, supra note 52. 
 220 Stenson, supra note 4; see also Tolstoi, supra note 52. 
 221 Tolstoi, supra note 52.  “Monographs are point papers on particular products 
or ingredients that contain safety and efficacy information.”  HHS Report, supra note 
2, at 22. 
 222 Tolstoi, supra note 52. 
 223 Id. 
 224 Id. 
 225 EXECUTIVE BRIEFING, supra note 68. 
 226 HHS Report, supra note 2, at 22.  The HHS Report recommends a 
collaboration with the NIH in “setting a research agenda addressing safety issues” in 
order to “increase the quality and quantity of clinical data” in order to “obtain vital 
information to adequately assess signals generated by the adverse event reporting 
system.”  Id. 
 227 Id. 
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system.”228  There are currently some federally funded studies on 
dietary supplements in progress.229  The process of researching and 
analyzing results, however, is a time consuming and costly project, 
and it may not be feasible for the FDA or the government to fund this 
alone.  Commentators have suggested the creation of a compulsory 
system where supplement manufacturers contribute money, based on 
their market share, to a fund to pay for clinical trials.230  This would 
benefit consumers because studies would be conducted, and would 
benefit manufacturers because they would not carry the burden of 
paying for individual studies.231  Requiring manufacturers to 
contribute money for use in clinical trials, however, may discourage 
manufacturers from producing these products.232  Without a patent 
process for herbal supplements, these research costs would be 
imposed upon manufacturers without providing economic safeguards 
to make such investments less financially risky.233 
The DSHEA originally allotted $5 million annually for the ODS; 
however, the ODS is consistently underfunded, receiving 
approximately one-fifth of the allotted amount.234  The absence of 
sufficient funding has prevented the ODS from being able to address 
individual inquiries and has limited its research abilities.235  One 
commentator argues that the ODS can increase consumer protection 
by distributing information, but only if the ODS is given adequate 
funding and staffing.236  If the ODS were adequately funded, it would 
have the ability to obtain information on the beneficial and 
dangerous aspects of dietary supplements and inform consumers of 
these aspects.237 
Although research on different fronts is arguably helpful in 
attaining supplement information, there is a sound argument that 
the manufacturer, and not the taxpayer, should be responsible for all 
of the costs of research because it is the manufacturer who ultimately 
profits from the sale of these supplements.  The research and 
evaluation of the results would provide vital information regarding 
 
 228 Id. 
 229 Stenson, supra note 4. 
 230 Termini, supra note 13, at 286. 
 231 Id. 
 232 See supra notes 202-05. 
 233 Id. 
 234 Sloane, supra note 9, at 337. 
 235 Id. 
 236 Id. at 339. 
 237 Id. 
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these dietary supplements.238  If there is sufficient information to 
educate manufacturers, the FDA, and consumers, there may be no 
need to create a stricter scheme for dietary supplements.239  Part of 
the problem is that not enough is known about the dangers of these 
products.240  If such dangers were identified, the FDA would arguably 
be better equipped to determine whether a dietary supplement is 
“adulterated,” and could then react within their present DSHEA 
powers.241 
H.  Current Efforts 
One goal of the Ten Year Plan involves establishing GMPs for 
dietary supplements.242  The FDA is working to establish GMPs for 
dietary supplements, which will help to both standardize dietary 
supplements and improve their quality.243  HHS has recommended 
the creation of GMPs to help prevent contamination of 
supplements.244  GMPs would lessen some of the dangers of dietary 
supplements, such as contamination and differences in strength.245  
The GMPs alone, however, would not be an effective remedy because 
they do not test the safety of the supplement.246  Supplements may 
have inherently dangerous side effects or interactions with other 
drugs, and GMPs would not address this problem.247  Yet, GMPs would 
be a valuable tool, especially if used in combination with other 
methods aimed at the inherent dangers of supplements. 
A national certification system designed for dietary supplements 
is another alternative.248  The United States Pharmacopeia (“USP”) is 
initiating a pilot program for such a certification system.249  The USP 
presently sets standards for prescription and over-the-counter 
 
 238 See HHS Report, supra note 2, at 22-23. 
 239 See id. at 22 (noting that “[p]erhaps the largest problem the FDA faces is the 
paucity of scientifically robust research on dietary supplements that is available in the 
event that a particular supplement product or ingredient generates a signal of 
possible public health concern”). 
 240 Id. 
 241 See PART I, for a discussion of the FDA’s present DSHEA powers. 
 242 TEN YEAR PLAN, supra note 107.  Section I.B. states that a CFSAN goal is to 
publish good manufacturing practices, and once issued, to “establish an outreach 
program to small business manufacturers and an ongoing inspection program.”  Id. 
 243 Stenson, supra note 4. 
 244 Hager, supra note 207. 
 245 See Stenson, supra note 4. 
 246 See id. 
 247 For examples of such dangers, see supra note 46. 
 248 Stenson, supra note 4. 
 249 Id. 
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medications.250  Once the national certification system is established 
for dietary supplements, manufacturers that meet the necessary 
requirements would be allowed to place a certification mark on their 
product labels.251  This certification mark would be a sign to the 
consumer that the products are of a particular quality and that they 
contain only the ingredients on the label.252  This process would help 
consumers choose dietary supplements, however, as the HHS Report 
notes, this system would have limited capability to protect consumers 
because “it would be voluntary; it would not address botanicals’ 
health claims or safety issues, and United States Pharmacopeia would 
not enforce adherence to these standards.”253 
I.  Broadening the FDA’s Power to Act Against Supplements 
Some argue that the FDA’s power should be broadened in the 
area of dietary supplement regulation.254  One suggestion is that the 
FDA could better regulate in this area if given wider powers once a 
health threat is discovered, without altering the present scheme to 
require pre-market clearance.255  Under this scheme, once a health 
threat is found, the FDA should have the power to force ingredient 
changes, or pull the product from the market completely.256  This 
differs from the present regulatory scheme, which requires the FDA 
to bear the burden of proving that the product presents “a significant 
or unreasonable risk of illness or injury” prior to taking action against 
it.257 
Another suggestion is to empower the FDA to act against an 
entire supplement class, broadening its current powers which only 
permit the FDA to act against individual products.258  These broader 
powers would be highly advantageous because the FDA would have 
the ability to act simultaneously against many supplements that pose 
the same risk, instead of going after one at a time.259 
 
 250 Id. 
 251 Id. 
 252 Id. 
 253 HHS Report, supra note 2, at 23. 
 254 See, e.g., Kaiser, supra note 15, at 1273. 
 255 Id. 
 256 Id. 
 257 21 U.S.C. § 342 (f)(1)(A) (2002). 
 258 Kaiser, supra note 15, at 1273. 
 259 See id. 
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J.  Burden Shifting Through Legislative Change 
A different proposal is to treat dietary supplements as food 
additives.260  This would require a change in the law, and would 
broaden the FDA’s power by eliminating its burden of proving a 
product unsafe.261  With this method of regulation, if the FDA 
determines that a supplement is unsafe, the manufacturer would 
then bear the burden of proving that the product is safe.262  To gain 
admission to the market, this system would require proof of safety, 
but not efficacy.263  A similar approach would be to change the statute 
to require manufacturers to “substantiate the safety” of its products.264  
This would be helpful to the FDA in its enforcement efforts because 
the burden of proving a product’s safety is shifted to the 
manufacturer.265  These processes would help protect consumers from 
dangerous products, however, any proposed change of the statute 
giving the FDA greater power would possibly face lobby efforts from 
the powerful supplement industry.266 
K.  Granting Prescription Status to Particular Supplements 
A final solution is to give certain dietary supplements 
prescription status, as some states are doing with ephedrine.267  
Product classes that pose a serious threat when taken as directed, that 
may be improperly used, or that have serious interactions with 
medications, could be given prescription status.268  Granting these 
 
 260 Schindler, supra note 14, at 280. 
 261 Id. 
 262 Id. 
 263 Id. 
 264 Gilhooley, supra note 33, at 128.  Professor Gilhooley notes that “[a] major 
weakness in the DSHEA is that it does not impose on all dietary supplements the 
burden and obligation to affirmatively substantiate their safety.”  Id.  Professor 
Gilhooley explains that “[i]f manufacturers had to substantiate safety, they would 
have to perform tests, in accordance with scientific standards, to determine risks and 
establish a safe level.  They would have a responsibility to follow-up on adverse 
reaction reports, and undertake whatever testing or changes scientists would 
consider necessary to assure safety.”  Id. at 119. 
 265 See id. at 128. 
 266 See Colloton, supra note 27, at 496-97 (noting the enormity of the dietary 
supplement industry, and stating that “[p]rior to the DSHEA, the dietary supplement 
industry and consumers struggled for decades with the U.S. Food and Drug 
Administration (“FDA”) in an effort to increase public access to both supplements 
and information regarding the benefits of supplements”). 
 267 See, e.g., TENN. CODE ANN. § 39-17-431 (1995); LA. REV. STAT. ANN. § 40:962.1 
(West 1995); MINN. STAT. ANN. § 152.135 (West 1998). 
 268 See, e.g., PART III.A. (discussing how some states have made ephedrine available 
only by prescription). 
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products prescription status would provide a greater opportunity for 
consumer education through the prescribing physician, the 
pharmacist, and the labeling and information provided by the 
pharmacy.269  When evaluating whether a supplement is adulterated, 
and therefore whether the FDA has authority to take action against it, 
the FDA looks at the safety when taken as the label directs, or in the 
absence of such directions, under normal use.270  Perhaps the FDA, 
however, should look at the health threat when taken in excess of the 
specific dosage directions to determine whether additional steps 
should be taken and whether prescription status should be granted.271  
This approach might make it more difficult for consumers to access 
certain supplements, and accordingly would run counter to one of 
the purposes of the DSHEA—greater availability.272  Requiring a 
consumer to obtain a prescription, however, is not as restrictive as 
completely removing a product from the market.  Additionally, 
imposing prescription status when necessary would further 
Congress’s goal of preventing the sale of dangerous supplements.273 
L.  Proposed Solution 
The solution best suited for this situation would appear to be a 
combination of changes designed to improve the safety of dietary 
supplements without unduly hindering Congress’s goal of increasing 
the availability of dietary supplements.274  To achieve this balance, 
three regulatory changes must be made.  First, Congress must shift 
the burden of proving a product’s safety onto the manufacturer, even 
if pre-market approval is not required.275  When the FDA wants to take 
 
 269 For example, a pharmacist may be required to counsel patients on their 
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action against a product, it should not first bear the burden of 
proving it unsafe; instead, the manufacturer should bear the burden 
of proving that the product at issue is safe.276  The FDA should then 
examine the data on which the manufacturer relies, and take action 
if the data is insufficient to demonstrate the product’s safety.  Second, 
Congress should amend the DSHEA to grant the FDA power to act 
against a dietary supplement class, as opposed to against each 
individual dietary supplement.277  If the FDA is acting against a class of 
products, it may be appropriate for manufacturers to prove product 
safety as a class, and divide researching and other costs incurred in 
making these proofs.  Third, supplements that are found to be 
dangerous in doses larger than that suggested on the label, if these 
higher doses are likely to be used despite warnings, should be 
granted prescription status on the federal level.278  Prescription status 
would help curb dangers of these products without completely 
withdrawing them from the market. 
These regulatory changes would increase the FDA’s ability to 
police the dietary supplement market, and would only interfere with 
the sale of potentially dangerous supplements.  This combination 
approach does not unduly limit the availability of dietary 
supplements, while still protecting consumers. 
The FDA’s present research efforts, along with research efforts 
of other organizations such as the NIEHS and the ODS, should be 
continued.279  Research can significantly assist the FDA in 
determining which dietary supplements are potential risks, thereby 
enabling the FDA to take appropriate action.280  The ODS should 
receive funding equivalent to, or greater than, the original amount 
granted in the DSHEA.281  GMPs and USPs are valuable in ensuring 
the quality, purity and strength of dietary supplements, and should 
be established.282 
Research, GMPs, and USPs, combined with the suggested 
regulatory modifications, will help ensure that products on the 
market are not contaminated and are not misbranded.  This will also 
provide the FDA with a greater opportunity for questioning, limiting 
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and removing dangerous products from the market. 
CONCLUSION 
Dietary supplements are freely available to consumers, and are 
placed on the market with minimal regulation.283  Approximately sixty 
percent of Americans take dietary supplements.284  Some dietary 
supplements have potentially dangerous side effects, and have been 
shown to interact with prescription medications.285  These dangerous 
side effects and interactions are largely discovered after the harm has 
occurred, because of the manner in which the current system 
operates.286  Additionally, once the FDA determines a dietary 
supplement poses a potential threat, the DSHEA limits the FDA’s 
power and assigns burdens in such a way as to hinder the FDA’s 
ability to promptly and effectively eliminate such dangers to 
consumers.  A change in this system is necessary.  Allowing the 
marketing of these potentially dangerous supplements until sufficient 
harm is reported by consumers, while hindering the FDA’s ability to 
act against potentially dangerous supplements, is unacceptable—
consumers need greater protection. 
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